Literature DB >> 17786723

Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma.

Brian McClune, Francis K Buadi, Naveed Aslam, Donna Przepiorka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17786723     DOI： 10.1080/10428190701573232

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  11 in total

1.  Intracranial hypertension following intrathecal administration of liposomal cytarabine.

Authors:  S Lunskens; L Lammertijn; D Deeren; B Bergmans; J Maertens; R Vandenberghe
Journal:  J Neurol       Date:  2010-08-13       Impact factor: 4.849

Review 2.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

3.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

4.  Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.

Authors:  Annie Brion; Faezeh Legrand; Fabrice Larosa; Françoise Schillinger; Francine Garnache-Ottou; Philippe Helias; Jean Fontan; Marian Heczko; Philippe Delaby; Etienne Daguindau; Jacqueline Vuillier; Adrien Chauchet; Eric Deconinck
Journal:  Invest New Drugs       Date:  2011-01-13       Impact factor: 3.850

5.  Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma.

Authors:  Jaime Gállego Pérez-Larraya; José Alberto Palma; María Carmona-Iragui; Roberto Fernández-Torrón; Pablo Irimia; Paula Rodríguez-Otero; Carlos Panizo; Eduardo Martínez-Vila
Journal:  J Neurooncol       Date:  2010-10-17       Impact factor: 4.130

6.  Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma.

Authors:  Kathrin Ostermann; Hendrik Pels; Annika Kowoll; Jan Kuhnhenn; Uwe Schlegel
Journal:  J Neurooncol       Date:  2010-10-17       Impact factor: 4.130

Review 7.  Intrathecal liposomal cytarabine: more friend than foe?

Authors:  Deepa Bhojwani; Ching-Hon Pui
Journal:  Leuk Lymphoma       Date:  2008-08

8.  Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.

Authors:  Alvaro Lassaletta; Blanca Lopez-Ibor; Elena Mateos; Marta Gonzalez-Vicent; Antonio Perez-Martinez; Julian Sevilla; Miguel A Diaz; Luis Madero
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

Review 9.  A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma.

Authors:  Maurilio Ponzoni; Silvia Govi; Giada Licata; Silvia Mappa; Antonio Giordano Resti; Letterio S Politi; Lorenzo Spagnuolo; Eliana Di Cairano; Claudio Doglioni; Andrés J M Ferreri
Journal:  Oncologist       Date:  2013-06-28

Review 10.  Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.

Authors:  Melanie Kripp; Ralf-Dieter Hofheinz
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.